Q-Line Biotech

Which are the latest news on Q-Line Biotech?

Why is Q-Line Biotech Ltd falling/rising?

As of 05-Sep, Q-Line Biotech Ltd's stock price is rising to 639.60, with a notable increase of 16.51% over the past week and 16.79% over the past month, significantly outperforming the Sensex. The stock is near its 52-week high and shows strong trading activity, indicating robust investor interest and a positive upward trend.

As of 05-Sep, Q-Line Biotech Ltd's stock price is rising, currently at 639.60, reflecting a change of 2.0 (0.31%) upward. The stock has shown strong performance over the past week, with a return of +16.51%, significantly outperforming the Sensex, which declined by -1.15% during the same period. Over the past month, the stock has also increased by +16.79%, while the Sensex fell by -2.91%. <BR><BR>Additionally, the stock is close to its 52-week high, being only 3.15% away from the high of Rs 659.75. Today's performance indicates that Q-Line Biotech has outperformed its sector by 3.85%. The stock is trading above its moving averages across various timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a strong upward trend. <BR><BR>Investor participation has risen, with a delivery volume of 2.02 lacs on September 3, marking an increase of 59.92% compared to the 5-day average delivery volume. This increase in trading activity indicates growing interest in the stock. Furthermore, the liquidity of the stock is adequate for trading, as it is based on 2% of the 5-day average traded value, allowing for a trade size of Rs 0.3 crore. All these factors contribute to the rising stock price of Q-Line Biotech Ltd.

What does Q-Line Biotech do?

Q-Line Biotech Ltd is a small-cap company in the healthcare services industry, previously known as POCT Services Private Limited. It has no recent sales or profit data, with a market cap of INR 1,344 Cr and a P/E ratio of 24.00.

Overview:<BR>Q-Line Biotech Ltd operates in the healthcare services industry and is classified as a small-cap company.<BR><BR>History:<BR>Q-Line Biotech Ltd was originally incorporated as "POCT Services Private Limited" in 2010. The company changed its name to "Q-Line Biotech Private Limited" on July 23, 2021. There is no sales or profit data available for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 1,344 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 24.00<BR>Industry P/E: 112<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.55<BR>Return on Equity: 23.32%<BR>Price-to-Book: 5.18<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

Who are the peers of the Q-Line Biotech?

Q-Line Biotech's peers include Vimta Labs, Krsnaa Diagnostics, Suraksha Diagnostics, Tarsons Products, 3B Blackbio, Laxmi Dental, Health X Platform, and One Global Services. Management risk varies from excellent to below average among peers, with Suraksha Diagnostics showing the highest 1-year return at 13.49% and Krsnaa Diagnostics the lowest at -29.80%.

Peers: The peers of Q-Line Biotech are Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., Tarsons Products, 3B Blackbio, Laxmi Dental, Health X Platfor, and One Global Serv.<BR><BR>Quality Snapshot: Excellent management risk is observed at Suraksha Diagno., Laxmi Dental, and One Global Serv, while Average management risk is found at Vimta Labs, Krsnaa Diagnost., 3B Blackbio, and the rest. Below Average management risk is noted at Tarsons Products and Health X Platfor. Growth is rated as Excellent for One Global Serv, Good for Suraksha Diagno. and Laxmi Dental, while Average growth is seen at Vimta Labs, Krsnaa Diagnost., 3B Blackbio, and the rest. Below Average growth is indicated for Tarsons Products and Health X Platfor. Capital Structure is Excellent for Vimta Labs, 3B Blackbio, and Health X Platfor, Good for Krsnaa Diagnost. and Suraksha Diagno., Average for Tarsons Products, and Excellent for Laxmi Dental.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suraksha Diagno. at 13.49%, while Krsnaa Diagnost. has the lowest at -29.80%. Q-Line Biotech's 1-year return is not available for comparison. Additionally, Laxmi Dental and One Global Serv have negative six-month returns.